Research Institute of Nephrology

Russian Federation, Russia

Research Institute of Nephrology

Russian Federation, Russia

Time filter

Source Type

Smirnov A.V.,Research Institute of Nephrology | Nesterova O.B.,Clinic of Internal Propedeutics | Suglobova E.D.,Research Institute of Nephrology | Golubev R.V.,Research Institute of Nephrology | And 9 more authors.
Terapevticheskii Arkhiv | Year: 2013

Aim. To evaluate the efficiency of using a succinate-containing dialysis solution (SCDS) in terminal renal failure patients treated with chronic hemodialysis (CHD). Subjects and methods. Ninety patients from two hemodialysis units took part in the crossover study and were allocated to 2 groups. For 6 months, study group patients received CHD using SCDS and control group patients had CHD with a standard bicarbonate dialysis solution after 3-month washout period followed by decussation. The time course of changes in blood biochemical parameters, 24-hour ECG monitoring data, and quality of life indicators were estimated in the patients. Results. After using acidosuccinate during hemodialysis, there was a significant reduction in the predialysis serum level of inorganic phosphate, a calcium phosphate product, y-glutamyl transpeptidase, urea, and aldosterone as compared to the control group. The blood concentration of total protein was also increased. After 6-month administration of acidosuccinate, the patients showed reductions in systolic blood pressure, heart rate, and the frequency and duration of ST-segment depression episodes. There were positive changes in the quality of life of patients according to the KDQOL-SF questionnaire. Conclusion. The use of SCDS in patients with CHD causes positive changes in a number of laboratory parameters and improves the physical and general status, and quality of life of patients.


Smirnov A.V.,Saint Petersburg State University | Vasilyeva I.A.,Research Institute of Nephrology | Nesterova O.B.,Saint Petersburg State University | Golubev R.V.,Research Institute of Nephrology | And 3 more authors.
Terapevticheskii Arkhiv | Year: 2014

Aim: To assess changes in quality of life (QL) and cognitive functions in patients with end-stage renal failure (ESRF) treated with hemodialysis using a succinate-containing dialyzing solution (SCOS). Subjects and methods: Sixty-seven patients with ESRF on hemodialysis using SCDS were examined. The investigators determined QL indicators using a Russianized variant of the Kidney Disease Quality of Life Short Form (KDQOL-SF) and the indicators of cognitive functions by the Benton visual retention test intended to evaluate visual short-term memory. The 6-minute walk test was used to evaluate exercise tolerance. The patients were examined before and 6 months after initiation of SCDS use. Results: Following 6 months of SCDS treatment, the patients showed positive changes in a number of QL indicators. Their exercise capacity (p=0.03) and the quality of sleep (p=0.03), and social interaction (p=0.02) were improved. The magnitude of the complaints related to disease and treatment decreased (p=0.001). The level of patient frustration was reduced (p<0.001). Different limitations associated with chronic kidney disease and dialysis therapy came to disturb the patients to a lesser degree (p=0.02). The Bentoin visual retention test exhibited fewer errors (p=0.04). Conclusion: Hemodialysis treatment with SCDS improved a number of QL indicators and cognitive functions in the patients.

Loading Research Institute of Nephrology collaborators
Loading Research Institute of Nephrology collaborators